Insulet Corporation Reports the US FDA’s Clearance of Omnipod 5 Automated Insulin Delivery System for Type 2 Diabetes
Shots:
- The US FDA has cleared the company’s Omnipod 5 Automated Insulin Delivery System for type 2 diabetes patients (≥18yrs.)
- The SECURE-T2D trial investigated Omnipod 5 for T2D. Results showed reduced HbA1c by 0.8% overall (2.1% in those with HbA1c ≥9%), decreased time in hyperglycemia & daily insulin dose plus increased time in range by 4.8hrs. per day without raising time in hypoglycemia with an improved diabetes distress
- Omnipod 5 is a tubeless AID system that works with a continuous glucose monitor to automatically manage highs & lows. It eases diabetes management and automatically adjusts insulin every 5 minutes with SmartAdjust technology
Ref: Insulet | Image: Insulet
Related News: Insulet’s Omnipod 5 Receives the US FDA’s Clearance for Type 1 Diabetes in Children Aged ≥2 Years
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
